Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter — ultra-fast Hanzi study All 1,152 characters from the aioLingua manual Abstract • About • The 20 audio files ← aioLingua Chinese Online ← Chinese aioLingua PDF

Liver Diseases

Free Subscription Articles published in J Gastroenterol Retrieve available abstracts of 83 articles: HTML format

Single Articles

December 2025
1. REN B, Li H, Liu S, Huang Z, et al
   Hic-5 deficiency attenuates MAFLD by inhibiting neutrophils migration via the CXCL1-CXCR2 axis.
   J Gastroenterol. 2025;60:1535-1553.
   PubMed     Abstract available
   
   
   
2. TSURUSAKI M, Sofue K, Murakami T, Tanigawa N, et al
   Evidence for imaging-based diagnosis of liver metastases from colorectal cancer.
   J Gastroenterol. 2025;60:1471-1480.
   PubMed     Abstract available
   
   
   November 2025
3. INADA H, Kurano S, Miyamoto H, Onishi M, et al
   TP53 mutation predicts resistance to immune checkpoint inhibitor-based therapy in intrahepatic cholangiocarcinoma.
   J Gastroenterol. 2025 Nov 17. doi: 10.1007/s00535-025-02320.
   PubMed     Abstract available
   
   
   
4. ZHOU LX, He CH, Dong H, Gao TM, et al
   Validation of Baveno VII criteria for recompensation in patients with decompensated cirrhosis treated by laparoscopic splenectomy and azygoportal disconnection.
   J Gastroenterol. 2025 Nov 8. doi: 10.1007/s00535-025-02317.
   PubMed     Abstract available
   
   
   
5. HINO K, Nishina S, Yanatori I
   Ferroptosis: biology and role in liver disease.
   J Gastroenterol. 2025;60:1339-1361.
   PubMed     Abstract available
   
   
   
6. TAKEMURA Y, Ueda Y, Takemura R, Mita J, et al
   Current status of waitlist mortality and transplant probability for adult candidates with chronic end-stage liver disease for deceased donor liver transplantation under the Model for End-Stage Liver Disease score-based allocation policy in Japan.
   J Gastroenterol. 2025;60:1414-1426.
   PubMed     Abstract available
   
   
   October 2025
7. TAHATA Y, Hikita H, Takaki A, Kurosaki M, et al
   Long-term changes in hepatic reserve and prognosis after direct-acting antiviral treatment in patients with hepatitis C virus-related decompensated cirrhosis: a five-year follow-up study of a Japanese phase 3 trial.
   J Gastroenterol. 2025 Oct 30. doi: 10.1007/s00535-025-02312.
   PubMed     Abstract available
   
   
   
8. MAESAKA K, Hikita H, Tahata Y, Nishioka C, et al
   Comparative analysis of lenvatinib use after atezolizumab plus bevacizumab versus lenvatinib as first-line therapy in unresectable hepatocellular carcinoma.
   J Gastroenterol. 2025 Oct 25. doi: 10.1007/s00535-025-02308.
   PubMed     Abstract available
   
   
   
9. IWASA T, Miwa T, Utakata Y, Oi M, et al
   Development of overt hepatic encephalopathy increases mortality in patients with cirrhosis: a multicenter retrospective cohort study.
   J Gastroenterol. 2025 Oct 17. doi: 10.1007/s00535-025-02309.
   PubMed     Abstract available
   
   
   
10. NAKADAI Y, Ojiro K, Kasuga R, Chu PS, et al
    Validation of novel scoring systems for acute decompensated cirrhosis identifies PBC as an independent poor prognostic factor: a single-center Japanese cohort study.
    J Gastroenterol. 2025 Oct 12. doi: 10.1007/s00535-025-02310.
    PubMed     Abstract available
    
    
    
11. MIYAKE T, Yoshida O, Furukawa S, Sato Y, et al
    GPAM upregulation enhances hepatic fat deposition and reduces visceral adipose tissue in response to trans-fatty acids.
    J Gastroenterol. 2025 Oct 4. doi: 10.1007/s00535-025-02297.
    PubMed     Abstract available
    
    
    
12. FUJII H, Uchida-Kobayashi S, Kanamori A, Nadatani Y, et al
    Defining optimal fatty liver index thresholds for MASLD and MetALD using controlled attenuation parameter as reference.
    J Gastroenterol. 2025;60:1296-1309.
    PubMed     Abstract available
    
    
    
13. LEE J, Cha JH, Cho HS, Yang K, et al
    The PNPLA3 I148M variant is associated with immune cell infiltration and advanced fibrosis in MASLD: a prospective genotype-phenotype study.
    J Gastroenterol. 2025;60:1284-1295.
    PubMed     Abstract available
    
    
    August 2025
14. OHAMA H, Hiraoka A, Tada T, Hirooka M, et al
    Potential role of Geriatric Nutritional Risk Index as a risk factor for immune-mediated adverse events during durvalumab plus tremelimumab therapy in unresectable hepatocellular carcinoma.
    J Gastroenterol. 2025 Aug 20. doi: 10.1007/s00535-025-02290.
    PubMed     Abstract available
    
    
    
15. KIDO H, Mizukoshi E, Yanagi M, Shihui L, et al
    Abnormalities of intracellular organelles in metabolic dysfunction-associated steatotic disease.
    J Gastroenterol. 2025;60:990-999.
    PubMed     Abstract available
    
    
    July 2025
16. YAMASAKI S, Nakahara T, Tsuge M, Yamaoka K, et al
    Metabolic dysfunction-associated steatotic liver disease affects the development of hepatocellular carcinoma after sustained virologic response in chronic hepatitis C patients.
    J Gastroenterol. 2025 Jul 7. doi: 10.1007/s00535-025-02270.
    PubMed     Abstract available
    
    
    
17. TSUTSUMI T, Kawaguchi T, Fujii H, Kamada Y, et al
    Low HDL cholesterol levels in women and hypertriglyceridemia in men: predictors of MASLD onset in individuals without steatosis.
    J Gastroenterol. 2025;60:891-904.
    PubMed     Abstract available
    
    
    
18. SUZUKI T, Matsuura K, Tahata Y, Hikita H, et al
    Posttreatment serum CXCL10 level stratifies survival in compensated and decompensated cirrhotic patients due to chronic hepatitis C virus infection after direct-acting antiviral therapy.
    J Gastroenterol. 2025 Jul 1. doi: 10.1007/s00535-025-02282.
    PubMed     Abstract available
    
    
    June 2025
19. OFUCHI T, Otsu H, Hosoda K, Ikehara T, et al
    VPS45 promotes the progression of hepatocellular carcinoma by recycling beta1 integrin to the cell membrane via the endocytic pathway.
    J Gastroenterol. 2025 Jun 20. doi: 10.1007/s00535-025-02278.
    PubMed     Abstract available
    
    
    
20. KAWAGISHI N, Suda G, Tahata Y, Hikita H, et al
    Pretreatment serum angiopoietin-2 predicts prognosis and liver functional reserve after successful HCV eradication with sofosbuvir and velpatasvir in patients with HCV-related decompensated cirrhosis.
    J Gastroenterol. 2025 Jun 20. doi: 10.1007/s00535-025-02275.
    PubMed     Abstract available
    
    
    
21. LIU WM, Chen CY, Ma HQ, Zhang QQ, et al
    Inhibition of liver cancer cell growth by metabolites S-adenosylmethionine and nicotinic acid originating from liver progenitor cells.
    J Gastroenterol. 2025;60:754-769.
    PubMed     Abstract available
    
    
    May 2025
22. ONO A, Hayes CN, Miura R, Kawaoka T, et al
    Noninvasive prediction of the clinical benefit of immunotherapy in hepatocellular carcinoma.
    J Gastroenterol. 2025 May 30. doi: 10.1007/s00535-025-02251.
    PubMed     Abstract available
    
    
    
23. DING H, Lv H, Sui M, Wang X, et al
    Interaction of neuropilin-1 and hepatocyte growth factor/C-Met pathway in liver fibrosis progression in hepatocyte-specific NRP-1 knockout mice.
    J Gastroenterol. 2025 May 26. doi: 10.1007/s00535-025-02262.
    PubMed     Abstract available
    
    
    
24. XIA M, Lu Y, Yin F, Cao Z, et al
    The external validation of Dallas Steatosis Index among Asian population: a useful tool for metabolic dysfunction-associated steatotic liver disease identification and prevention.
    J Gastroenterol. 2025;60:621-631.
    PubMed     Abstract available
    
    
    April 2025
25. ZHANG Y, Che N, Wang S, Meng J, et al
    Correction: Nrf2/ASPM axis regulated vasculogenic mimicry formation in hepatocellular carcinoma under hypoxia.
    J Gastroenterol. 2025 Apr 23. doi: 10.1007/s00535-025-02246.
    PubMed    
    
    
    
26. OURA K, Morishita A, Yano R, Manabe T, et al
    Circulating miR-485-3p as a biomarker for VEGF-associated therapeutic response to atezolizumab plus bevacizumab in hepatocellular carcinoma.
    J Gastroenterol. 2025 Apr 3. doi: 10.1007/s00535-025-02239.
    PubMed     Abstract available
    
    
    
27. HANAMATSU H, Suda G, Ohara M, Ogawa K, et al
    Elevated A2F bisect N-glycans of serum IgA reflect progression of liver fibrosis in patients with MASLD.
    J Gastroenterol. 2025;60:456-468.
    PubMed     Abstract available
    
    
    March 2025
28. MIWA T, Tsuruoka M, Ueda H, Abe T, et al
    Current management and future perspectives of covert hepatic encephalopathy in Japan: a nationwide survey.
    J Gastroenterol. 2025 Mar 7. doi: 10.1007/s00535-025-02232.
    PubMed     Abstract available
    
    
    
29. AOKI T, Kudo M, Nishida N, Ueshima K, et al
    Proposal of discontinuation criteria of atezolizumab plus bevacizumab after curative conversion therapy for unresectable early-to-intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept study.
    J Gastroenterol. 2025 Mar 7. doi: 10.1007/s00535-025-02233.
    PubMed     Abstract available
    
    
    
30. DU T, Huang Y, Lv Y, Yuan G, et al
    Liver fibrotic burden across the spectrum of hypothyroidism.
    J Gastroenterol. 2025;60:315-327.
    PubMed     Abstract available
    
    
    
31. WANG H, Liu Z, Fan H, Guo C, et al
    Association between advanced fibrosis and epigenetic age acceleration among individuals with MASLD.
    J Gastroenterol. 2025;60:306-314.
    PubMed     Abstract available
    
    
    February 2025
32. NISHIMURA T, Tada T, Akita T, Kondo R, et al
    Diagnostic performance of attenuation imaging versus controlled attenuation parameter for hepatic steatosis with MRI-based proton density fat fraction as the reference standard: a prospective multicenter study.
    J Gastroenterol. 2025 Feb 24. doi: 10.1007/s00535-025-02224.
    PubMed     Abstract available
    
    
    
33. TANAKA A, Notohara K, Tobari M, Abe M, et al
    A clinicopathological study of IgG4-related autoimmune hepatitis and IgG4-hepatopathy.
    J Gastroenterol. 2025 Feb 8. doi: 10.1007/s00535-025-02221.
    PubMed     Abstract available
    
    
    
34. KOGISO T, Ogasawara Y, Taniai M, Shimada E, et al
    Impact of ursodeoxycholic acid treatment on Fontan-associated liver disease.
    J Gastroenterol. 2025;60:210-221.
    PubMed     Abstract available
    
    
    
35. KURODA H, Abe T, Kamiyama N, Oguri T, et al
    Novel subharmonic-aided pressure estimation for identifying high-risk esophagogastric varices.
    J Gastroenterol. 2025;60:187-196.
    PubMed     Abstract available
    
    
    January 2025
36. WEN C, Tao H, Chen H, Pu W, et al
    Single-cell RNA sequencing and functional analysis reveal the role of altered glycosylation levels of hepatic macrophages in liver cirrhosis.
    J Gastroenterol. 2025 Jan 31. doi: 10.1007/s00535-025-02218.
    PubMed     Abstract available
    
    
    
37. ZHANG X, Li J, Yao Y, Zhou M, et al
    Migrasome-related prognostic signature TSPAN4 correlates with immune infiltrates and metabolic disturbances in hepatocellular carcinoma.
    J Gastroenterol. 2025 Jan 12. doi: 10.1007/s00535-025-02212.
    PubMed     Abstract available
    
    
    
38. KASAI Y, Ito T, Masui T, Nagai K, et al
    Liver transplantation for gastroenteropancreatic neuroendocrine liver metastasis: optimal patient selection and perioperative management in the era of multimodal treatments.
    J Gastroenterol. 2025;60:1-9.
    PubMed     Abstract available
    
    
    December 2024
39. ZHANG F, Wang YS, Li SP, Zhao B, et al
    Alpha-fetoprotein combined with initial tumor shape irregularity in predicting the survival of patients with advanced hepatocellular carcinoma treated with immune-checkpoint inhibitors: a retrospective multi-center cohort study.
    J Gastroenterol. 2024 Dec 23. doi: 10.1007/s00535-024-02202.
    PubMed     Abstract available
    
    
    
40. MIURA R, Ono A, Nakahara H, Shirane Y, et al
    Serum IL-6 concentration is a useful biomarker to predict the efficacy of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
    J Gastroenterol. 2024 Dec 9. doi: 10.1007/s00535-024-02185.
    PubMed     Abstract available
    
    
    
41. KAMADA Y, Sumida Y, Takahashi H, Fujii H, et al
    Utility of Mac-2 binding protein glycosylation isomer as an excellent biomarker for the prediction of liver fibrosis, activity, and hepatocellular carcinoma onset: an expert review.
    J Gastroenterol. 2024 Dec 9. doi: 10.1007/s00535-024-02179.
    PubMed     Abstract available
    
    
    
42. IMAI Y, Koizumi Y, Hiasa Y, Hirooka M, et al
    Standard technique in Japan for measuring hepatic venous pressure gradient.
    J Gastroenterol. 2024 Dec 9. doi: 10.1007/s00535-024-02182.
    PubMed     Abstract available
    
    
    
43. RABIU L, Zhang P, Afolabi LO, Saliu MA, et al
    Immunological dynamics in MASH: from landscape analysis to therapeutic intervention.
    J Gastroenterol. 2024;59:1053-1078.
    PubMed     Abstract available
    
    
    November 2024
44. CAO Z, Yang Y, Liu S, Sun L, et al
    FGFR2 fusions assessed by NGS, FISH, and immunohistochemistry in intrahepatic cholangiocarcinoma.
    J Gastroenterol. 2024 Nov 13. doi: 10.1007/s00535-024-02175.
    PubMed     Abstract available
    
    
    October 2024
45. LIU WJ, Wu WJ, Lin CL, Liu CJ, et al
    Impact of age at HBsAg seroclearance on hepatic outcomes and life expectancy in men with chronic HBV infection based on multi-state modeling of the natural history.
    J Gastroenterol. 2024 Oct 22. doi: 10.1007/s00535-024-02162.
    PubMed     Abstract available
    
    
    
46. UENO M, Takeda H, Takai A, Morimura H, et al
    Publisher Correction: CRAFITY score as a predictive marker for refractoriness to atezolizumab plus bevacizumab therapy in hepatocellular carcinoma: a multicenter retrospective study.
    J Gastroenterol. 2024 Oct 21. doi: 10.1007/s00535-024-02159.
    PubMed    
    
    
    
47. SOMA N, Uchida Y, Kouyama JI, Naiki K, et al
    Serum zinc levels as predictors of covert hepatic encephalopathy in patients with liver cirrhosis.
    J Gastroenterol. 2024 Oct 16. doi: 10.1007/s00535-024-02160.
    PubMed     Abstract available
    
    
    
48. KAWAGUCHI T, Fujishima Y, Wakasugi D, Io F, et al
    Effects of SGLT2 inhibitors on the onset of esophageal varices and extrahepatic cancer in type 2 diabetic patients with suspected MASLD: a nationwide database study in Japan.
    J Gastroenterol. 2024 Oct 11. doi: 10.1007/s00535-024-02158.
    PubMed     Abstract available
    
    
    
49. HANAI T, Nishimura K, Unome S, Miwa T, et al
    Response to letter to the editor regarding: "Alcohol-associated liver disease increases the risk of muscle reduction and mortality in patients with cirrhosis".
    J Gastroenterol. 2024 Oct 4. doi: 10.1007/s00535-024-02153.
    PubMed    
    
    
    
50. SANCHEZ-MONTEAGUDO A, Ripolles E, Murillo O, Domenech S, et al
    Profile of plasma microRNAs as a potential biomarker of Wilson's disease.
    J Gastroenterol. 2024;59:921-931.
    PubMed     Abstract available
    
    
    September 2024
51. KUNZLER IL, Da Croce MA, Fornari F
    Alcohol-associated liver disease increases the risk of muscle loss and mortality in patients with cirrhosis.
    J Gastroenterol. 2024 Sep 23. doi: 10.1007/s00535-024-02154.
    PubMed    
    
    
    
52. UENO M, Takeda H, Takai A, Morimura H, et al
    CRAFITY score as a predictive marker for refractoriness to atezolizumab plus bevacizumab therapy in hepatocellular carcinoma: a multicenter retrospective study.
    J Gastroenterol. 2024 Sep 18. doi: 10.1007/s00535-024-02150.
    PubMed     Abstract available
    
    
    
53. YAMAUCHI K, Maekawa S, Osawa L, Komiyama Y, et al
    Single-molecule sequencing of the whole HCV genome revealed envelope deletions in decompensated cirrhosis associated with NS2 and NS5A mutations.
    J Gastroenterol. 2024 Sep 3. doi: 10.1007/s00535-024-02146.
    PubMed     Abstract available
    
    
    
54. KAWAGUCHI T, Murotani K, Kajiyama H, Obara H, et al
    Effects of luseogliflozin on suspected MASLD in patients with diabetes: a pooled meta-analysis of phase III clinical trials.
    J Gastroenterol. 2024;59:836-848.
    PubMed     Abstract available
    
    
    August 2024
55. YU C, Tang Y, Liu M, Xu X, et al
    The risk stratification and predictive performance of a new combined polygenic risk score for hepatocellular carcinoma.
    J Gastroenterol. 2024 Aug 10. doi: 10.1007/s00535-024-02144.
    PubMed     Abstract available
    
    
    
56. ZHANG Y, Che N, Wang S, Meng J, et al
    Nrf2/ASPM axis regulated vasculogenic mimicry formation in hepatocellular carcinoma under hypoxia.
    J Gastroenterol. 2024 Aug 3. doi: 10.1007/s00535-024-02140.
    PubMed     Abstract available
    
    
    July 2024
57. HANAI T, Nishimura K, Unome S, Miwa T, et al
    Alcohol-associated liver disease increases the risk of muscle loss and mortality in patients with cirrhosis.
    J Gastroenterol. 2024 Jul 28. doi: 10.1007/s00535-024-02137.
    PubMed     Abstract available
    
    
    
58. HAO Y, Hao Z, Zeng X, Lin Y, et al
    Gut microbiota and metabolites of cirrhotic portal hypertension: a novel target on the therapeutic regulation.
    J Gastroenterol. 2024 Jul 19. doi: 10.1007/s00535-024-02134.
    PubMed     Abstract available
    
    
    
59. AMPUERO J, Aller R, Gallego-Duran R, Crespo J, et al
    The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis.
    J Gastroenterol. 2024;59:586-597.
    PubMed     Abstract available
    
    
    June 2024
60. MIWA T, Utakata Y, Hanai T, Aiba M, et al
    Acute kidney injury development is associated with mortality in Japanese patients with cirrhosis: impact of amino acid imbalance.
    J Gastroenterol. 2024 Jun 11. doi: 10.1007/s00535-024-02126.
    PubMed     Abstract available
    
    
    
61. WAKABAYASHI SI, Tamaki N, Kimura T, Umemura T, et al
    Natural history of lean and non-lean metabolic dysfunction-associated steatotic liver disease.
    J Gastroenterol. 2024;59:494-503.
    PubMed     Abstract available
    
    
    
62. HIROOKA M, Ogawa S, Koizumi Y, Yoshida Y, et al
    iATT liver fat quantification for steatosis grading by referring to MRI proton density fat fraction: a multicenter study.
    J Gastroenterol. 2024;59:504-514.
    PubMed     Abstract available
    
    
    
63. MINO M, Sano A, Kakazu E, Matsubara H, et al
    Differences in branched-chain amino acid to tyrosine ratio (BTR) among etiologies of chronic liver disease progression compared to healthy adults.
    J Gastroenterol. 2024;59:483-493.
    PubMed     Abstract available
    
    
    May 2024
64. ATSUKAWA M, Tsubota A, Kondo C, Toyoda H, et al
    ALBI score predicts morphological changes in esophageal varices following direct-acting antiviral-induced sustained virological response in patients with liver cirrhosis.
    J Gastroenterol. 2024 May 10. doi: 10.1007/s00535-024-02109.
    PubMed     Abstract available
    
    
    April 2024
65. FUJIWARA K, Kondo T, Fujimoto K, Yumita S, et al
    Clinical risk factors for portal hypertension-related complications in systemic therapy for hepatocellular carcinoma.
    J Gastroenterol. 2024 Apr 7. doi: 10.1007/s00535-024-02097.
    PubMed     Abstract available
    
    
    
66. CORNEJO-PAREJA I, Amiar MR, Ocana-Wilhelmi L, Soler-Humanes R, et al
    Non-alcoholic fatty liver disease in patients with morbid obesity: the gut microbiota axis as a potential pathophysiology mechanism.
    J Gastroenterol. 2024;59:329-341.
    PubMed     Abstract available
    
    
    March 2024
67. XIN HY, Zou JX, Sun RQ, Hu ZQ, et al
    Characterization of tumor microbiome and associations with prognosis in intrahepatic cholangiocarcinoma.
    J Gastroenterol. 2024 Mar 10. doi: 10.1007/s00535-024-02090.
    PubMed     Abstract available
    
    
    
68. WANG J, Zhang H, Chen L, Fu K, et al
    CircDCBLD2 alleviates liver fibrosis by regulating ferroptosis via facilitating STUB1-mediated PARK7 ubiquitination degradation.
    J Gastroenterol. 2024;59:229-249.
    PubMed     Abstract available
    
    
    February 2024
69. WU C, Li J, Jia H, Zhao J, et al
    Indoleamine 2,3-dioxygenase 1-mediated iron metabolism in macrophages contributes to lipid deposition in nonalcoholic steatohepatitis.
    J Gastroenterol. 2024 Feb 24. doi: 10.1007/s00535-024-02082.
    PubMed     Abstract available
    
    
    
70. NAMISAKI T, Sato S, Yoshiji H
    Role of combined aerobic and resistance exercise in liver cirrhosis.
    J Gastroenterol. 2024 Feb 8. doi: 10.1007/s00535-024-02078.
    PubMed    
    
    
    January 2024
71. KOBAYASHI T, Iwaki M, Nogami A, Kawamura N, et al
    Prediction of outcomes in patients with metabolic dysfunction-associated steatotic liver disease based on initial measurements and subsequent changes in magnetic resonance elastography.
    J Gastroenterol. 2024;59:56-65.
    PubMed     Abstract available
    
    
    
72. HANAI T, Nishimura K, Unome S, Miwa T, et al
    A survey questionnaire evaluating physical activity patterns and determinants in patients with chronic liver disease.
    J Gastroenterol. 2024;59:45-55.
    PubMed     Abstract available
    
    
    December 2023
73. KAWAGUCHI T, Kawaguchi A, Hashida R, Nakano D, et al
    Resistance exercise in combination with aerobic exercise reduces the incidence of serious events in patients with liver cirrhosis: a meta-analysis of randomized controlled trials.
    J Gastroenterol. 2023 Dec 30. doi: 10.1007/s00535-023-02060.
    PubMed     Abstract available
    
    
    
74. ICHITA C, Goto T, Shimizu S
    Considerations for evaluating antibiotic prophylaxis in cirrhotic patients with upper gastrointestinal bleeding in real-world data.
    J Gastroenterol. 2023 Dec 19. doi: 10.1007/s00535-023-02066.
    PubMed    
    
    
    
75. UENO M, Fujiwara T, Tokumasu H, Mizuno M, et al
    Reply to "Considerations for evaluating antibiotic prophylaxis in cirrhotic patients with upper gastrointestinal bleeding in real-world data".
    J Gastroenterol. 2023 Dec 13. doi: 10.1007/s00535-023-02067.
    PubMed    
    
    
    November 2023
76. YANG Z, Shi M, Liang Y, Zhang F, et al
    Three-dimensional chromatin landscapes in hepatocellular carcinoma associated with hepatitis B virus.
    J Gastroenterol. 2023 Nov 5. doi: 10.1007/s00535-023-02053.
    PubMed     Abstract available
    
    
    October 2023
77. WANG H, Li Y, Pu X, Liang X, et al
    MGAT5/TMEM163 variant is associated with prognosis in ursodeoxycholic acid-treated patients with primary biliary cholangitis.
    J Gastroenterol. 2023 Oct 16. doi: 10.1007/s00535-023-02045.
    PubMed     Abstract available
    
    
    
78. TAHATA Y, Hikita H, Mochida S, Enomoto N, et al
    Posttreatment liver function, but not baseline liver function stratifies patient survival after direct-acting antiviral treatment in decompensated cirrhosis with hepatitis C virus.
    J Gastroenterol. 2023 Oct 13. doi: 10.1007/s00535-023-02039.
    PubMed     Abstract available
    
    
    
79. CRANE H, Gofton C, Sharma A, George J, et al
    MAFLD: an optimal framework for understanding liver cancer phenotypes.
    J Gastroenterol. 2023;58:947-964.
    PubMed     Abstract available
    
    
    September 2023
80. KADO A, Tsutsumi T, Yotsuyanagi H, Ikeuchi K, et al
    Noninvasive approach to indicate risk factors of nonalcoholic steatohepatitis overlapping autoimmune hepatitis based on peripheral lymphocyte pattern.
    J Gastroenterol. 2023 Sep 14. doi: 10.1007/s00535-023-02038.
    PubMed     Abstract available
    
    
    
81. WEI M, Chen Y, Wang M, Li J, et al
    Correction: Partial splenic embolization combined with endoscopic therapies and vasoconstrictive drugs reduces rebleeding in cirrhosis patients with acute variceal bleeding and hypersplenism: a multicenter randomized controlled trial.
    J Gastroenterol. 2023 Sep 12. doi: 10.1007/s00535-023-02036.
    PubMed    
    
    
    
82. OZONO Y, Kawakami H, Uchiyama N, Hatada H, et al
    Current status and issues in genomic analysis using EUS-FNA/FNB specimens in hepatobiliary-pancreatic cancers.
    J Gastroenterol. 2023 Sep 12. doi: 10.1007/s00535-023-02037.
    PubMed     Abstract available
    
    
    
83. LIU C, Zhu S, Zhang J, Wu P, et al
    Global, regional, and national burden of liver cancer due to non-alcoholic steatohepatitis, 1990-2019: a decomposition and age-period-cohort analysis.
    J Gastroenterol. 2023 Sep 4. doi: 10.1007/s00535-023-02040.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.